A biotechnology sponsor engineered a next-generation bispecific monoclonal antibody designed to mitigate pathological clot formation and disrupt platelet–leukocyte aggregates in immune-thrombotic conditions. We conducted a systematic indication prioritization strategy, identifying and validating lead opportunities across three distinct therapeutic areas, each supported by mechanistic and pathophysiological evidence. Our findings directly informed the Series A fundraising narrative and contributed to the expansion of the clinical development pipeline for the asset.